‘Buzz about AI’ lends to Linguamatics win

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/	Yuichiro Chino)
(Image: Getty/ Yuichiro Chino)

Related tags: awards, AI, Natural Language Processing, Data, Data management

Linguamatics’ platform was recognized for its ability to generate insights from unstructured and semi-structured data.

Frost & Sullivan presented its Global Product Leadership Award to Linguamatics following the market acceptance of the company’s I2E NLP text mining platform, which enables users to integrate artificial intelligence (AI) into research operations.  Frost & Sullivan recognized the company after reviewing market offerings and capabilities for performance.

There is a huge buzz about AI at the minute, and health care and pharma organizations are struggling to work out what the best applications are, how they can get value, and who they should work with,” ​said Jane Reed, head of life science strategy at Linguamatics.

“At all stages, natural language processing, an AI technology, can be used to find the key facts buried in the unstructured text (literature, patents, internal reports, news feeds, patient forum, clinical trial reports, electronic medical records) and surface these in an easy-to-digest manner,”​ she told us.

According to Reed, the demand for sophisticated tools that can handle the data transformation of AI and natural language processing (NLP) will increase.

Frost & Sullivan stated that the platform’s flexibility of application was a key component of its recognition. I2E can be applied across gene-disease mapping and target identification, biomarker discovery, regulatory compliance management, drug safety, clinical trial analysis, drug patent landscape reporting and analysis, real-world data analysis, and identification of clinical care gaps.

I2E can extract and search language, and can be plugged into automated workflows for database operations. Linguamatics also recently built iScite, a software-as-a-service (SaaS) AI-based text analytics solution using the company’s NLP technology. 

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars